| # | Drug | Count |
|---|---|---|
| 0 | TACROLIMUS | 36 |
| 1 | RITUXIMAB | 35 |
| 2 | PREDNISONE | 34 |
| 3 | TACROLIMUS EXTENDED-RELEASE CAPSULES | 34 |
| 4 | TACROLIMUS OINTMENT 0.1% | 34 |
| 5 | MYCOPHENOLATE MOFETIL | 25 |
| 6 | MYCOPHENOLATE MOFETIL HYDROCHLORIDE | 25 |
| 7 | BEVACIZUMAB | 24 |
| 8 | CYCLOPHOSPHAMIDE | 22 |
| 9 | CYCLOPHOSPHAMIDE FOR INJECTION | 22 |
| # | Drug | Count | Frequency |
|---|---|---|---|
| 0 | BULEVIRTIDE | 1 | 0.0104 |
| 1 | TERLIPRESSIN | 3 | 0.0091 |
| 2 | INOTUZUMAB OZOGAMICIN | 11 | 0.0037 |
| 3 | SELADELPAR LYSINE | 1 | 0.0036 |
| 4 | CYSTEAMINE HYDROCHLORIDE | 2 | 0.0030 |
| 5 | GAS RELIEF | 1 | 0.0020 |
| 6 | CYSTEAMINE BITARTRATE | 2 | 0.0019 |
| 7 | ESTRADIOL CYPIONATE | 1 | 0.0017 |
| 8 | ATOVAQUONE | 12 | 0.0015 |
| 9 | DOCUSATE SODIUM 50 MG SENNOSIDES 8.6 MG | 1 | 0.0013 |
| # | Drug class | Count |
|---|---|---|
| 0 | Corticosteroid [EPC] | 70 |
| 1 | Loop Diuretic [EPC] | 38 |
| 2 | CD20-directed Cytolytic Antibody [EPC] | 35 |
| 3 | Vascular Endothelial Growth Factor Inhibitor [EPC] | 24 |
| 4 | Nucleoside Metabolic Inhibitor [EPC] | 23 |
| 5 | Aldosterone Antagonist [EPC] | 22 |
| 6 | Alkylating Drug [EPC] | 22 |
| 7 | Proton Pump Inhibitor [EPC] | 22 |
| 8 | Platinum-based Drug [EPC] | 15 |
| 9 | Kinase Inhibitor [EPC] | 14 |
| # | Drug class | Count | Frequency |
|---|---|---|---|
| 0 | CD22-directed Immunoconjugate [EPC] | 11 | 0.0037 |
| 1 | Antimalarial [EPC] | 12 | 0.0011 |
| 2 | Antiprotozoal [EPC] | 12 | 0.0011 |
| 3 | Claudin 18.2-directed Cytolytic Antibody [EPC] | 1 | 0.0007 |
| 4 | Antimetabolite Immunosuppressant [EPC] | 11 | 0.0005 |
| 5 | alpha-Hydroxy Acid [EPC] | 1 | 0.0005 |
| 6 | SARS-CoV-2 Nucleotide Analog RNA Polymerase Inhibitor [EPC] | 6 | 0.0005 |
| 7 | Cytomegalovirus Nucleoside Analog DNA Polymerase Inhibitor [EPC] | 9 | 0.0004 |
| 8 | Prostacyclin Receptor Agonist [EPC] | 8 | 0.0003 |
| 9 | Carnitine Analog [EPC] | 1 | 0.0003 |